Table of Contents
- Trial overview
- Study design and treatment groups
- Who can participate
- Main outcomes measured
- What the results mean for patients
Trial overview
The listed study is an interventional study, which means researchers assign treatments and then measure the results.[1] It is a Phase 2 trial, so it is focused on learning more about how well the treatment works while also collecting more information about safety and response.[1]
This trial is authorised and includes 169 participants.[1] The condition being studied is hormone naive prostate cancer, which means prostate cancer in people who have not yet had hormone treatment.[1]
Study design and treatment groups
The trial compares darolutamide with several androgen deprivation therapy (ADT) options, and Triptorelin Pamoate is one of the ADT treatments listed in the study.[1] Other study drugs include degarelix, leuprorelin, triptorelin, and goserelin.[1]
The trial summary says the ADT arm is used as an internal control, meaning it serves as a comparison group inside the same study.[1] This helps researchers judge whether the main study arm reaches similar PSA response rates after 24 weeks.[1]
Who can participate
The target population is people with hormone naive prostate cancer.[1] In simple terms, these are patients who have prostate cancer but have not yet received hormone treatment.[1]
The trial data do not list more detailed entry rules in the source provided, so the clearest eligibility information is the disease group itself.[1]
Main outcomes measured
The primary endpoint is PSA response at 24 weeks.[1] PSA stands for prostate-specific antigen, a blood marker used in prostate cancer follow-up.[1]
In this trial, PSA response means a decline of at least 80% from the baseline value, which is the starting measurement before treatment begins.[1] The brief summary says the main objective is to show that darolutamide produces PSA response rates in the range seen with 24 weeks of ADT.[1]
What the results mean for patients
For patients, this trial is mainly about comparing treatment responses in early prostate cancer before hormone therapy has been used.[1] The study does not report final results in the source provided, so it is best viewed as a research effort to measure how well the treatment approach performs over 24 weeks.[1]
Because Triptorelin Pamoate is listed among the ADT options, it is part of the treatment comparison rather than the only focus of the study.[1] The main patient-centered question is whether the treatment strategy can achieve a strong PSA drop in this group of men with hormone naive prostate cancer.[1]
